Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20

Latest Articles in cipla

Equity Indices Close Flat, Pharma Stocks Hit But PSU Banks Gain

The BSE S&P Sensex wound up 37 points or 0.1 per cent lower at 38,370 while the Nifty 50 lost by 14 points or 0.12 per cent at 11,308.

Read More

Equity indices dip on weak global cues, pharma stocks hit

Equity indices dip on weak global cues, pharma stocks hit

Read More

Equity indices close in the green, Cipla gains 9.5 pc

Equity indices close in the green, Cipla gains 9.5 pc

Read More

Equity indices trade higher, pharma and auto stocks gain

Equity indices trade higher, pharma and auto stocks gain

Read More

Cipla Gets India Approval To Sell COVID-19 Drug Favipiravir

The Drug Controller General of India granted Cipla accelerated approval to make and sell favipiravir in an effort to meet the "urgent and unmet" need for COVID-19 treatment options in the country

Read More

COVID-19: DCGI nod to Jubilant Generics to manufacture, sell remdesivir for 'restricted emergency use'

COVID-19: DCGI nod to Jubilant Generics to manufacture, sell remdesivir for 'restricted emergency use'

Read More

Cipla Receives Final Approval For Generic Version Of Shire’s Firazyr®

Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

Read More

Gilead Prices COVID-19 Drug Remdesivir At $2,340 Per Patient In Developed Nations

Cipla's version is priced at less than 5,000 Indian rupees ($66.24), while Hetero Lab's version is priced at 5,400 rupees ($71.54).

Read More

India's Hetero Prices Experimental COVID-19 Drug Remdesivir At $71 Per 100 Mg Vial

India has approved the generic versions made by Cipla and Hetero for restricted emergency use in severe COVID-19 cases.

Read More

Cipla To Price Remdesivir Version For COVID-19 Under 5,000 Rupees

The expectations suggest sales of between $2 billion and $3 billion between 2020 and 2021 at a price of $1,000 to $2,000 per course, according to Jefferies analyst Michael Yee.

Read More

Sensex Closes 180 Points Up, Glenmark Pharma Jumps 27 Pc

Cipla's stock jumped by 2.9 per cent to Rs 655.80 per unit after it announced the launch of remdesivir under its brand name Cipremi.

Read More

Glenmark, Cipla Stocks Surge After Nod To Launch Drugs For Mild-to-moderate COVID-19 Infections

At the same time, Cipla's stock jumped by 4.3 per cent to Rs 664.45 per unit after it announced the launch of remdesivir under its brand name Cipremi.

Read More

Equity indices trade higher as banking, pharma stocks rally

Equity indices trade higher as banking, pharma stocks rally

Read More

Cipla expands partnership with Roche Pharma to improve access for oncology medicines

Cipla expands partnership with Roche Pharma to improve access for oncology medicines

Read More

Cipla Receives USFDA’s Green Flag For Generic Inhaler

Leading pharmaceutical firm Cipla has received final approval for a generic version of Proventil HFA Inhalation Aerosol used to treat acute bronchospasm or asthmatic symptoms

Read More